Adverse Events Could Predict Neuroendocrine Tumor Therapy Effectiveness
A study recently published in the journal ESMO Open has documented new biomarkers which may be able to predict efficacy outcomes of antiangiogenic therapies (such as surufatinib) in patients diagnosed with neuroendocrine…